Skip to main content
Chordia Therapeutics,Inc logo

Chordia Therapeutics,Inc — Investor Relations & Filings

Ticker · 190A ISIN · JP3283730004 T Professional, scientific and technical activities
Open in API
Filings indexed 18 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country JP Japan
Listing T 190A

About Chordia Therapeutics,Inc

https://www.chordiatherapeutics.com/en.…

Chordia Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the research and development of novel cancer therapies. The company focuses on discovering and developing first-in-class, small-molecule drugs that target RNA deregulation, a key driver in various cancers. Its mission is to create life-changing treatments for patients by advancing a pipeline of innovative drug candidates from preclinical research through clinical trials.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 100% confidence The document is a 'Confirmation Letter' (確認書) filed under Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act. It serves as an officer certification attesting to the accuracy of a semi-annual report. According to the 'CERTIFICATION RULE', documents that are primarily officer certifications or attestations, even if they reference a report (in this case, a semi-annual report), should be classified as Regulatory Filings (RNS) rather than the report itself. H1 2026
2026-04-14 Japanese
半期報告書－第9期(2025/09/01－2026/08/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-Annual Report) filed by Chordia Therapeutics Inc. with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MD&A), and information on share capital and stock options for the interim period ending February 28, 2026. This fits the definition of an Interim/Quarterly Report (IR). H1 2026
2026-04-14 Japanese
確認書
Audit Report / Information Classification · 95% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-4-2 of the Financial Instruments and Exchange Act of Japan. This is a mandatory regulatory filing that accompanies an Annual Securities Report (Yuuka Shouken Houkokusho) to certify the accuracy of the report's contents. Since it is a specific regulatory filing required by the Japanese FSA and does not fit into the other categories like 10-K or IR, it is classified as a Regulatory Filing (RNS). FY 2025
2025-11-21 Japanese
有価証券報告書－第8期(2024/09/01－2025/08/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It contains detailed financial statements, business descriptions, management analysis, and audit information for the fiscal year ending August 31, 2025. It is a comprehensive regulatory filing, not an announcement or a summary. FY 2025
2025-11-21 Japanese
有価証券届出書（参照方式）
Capital/Financing Update Classification · 95% confidence The document is a '有価証券届出書' (Securities Registration Statement) filed with the Kanto Local Finance Bureau by Chordia Therapeutics Inc. It details the issuance of new share acquisition rights (stock options/warrants) to raise capital for clinical trials. This type of filing is a formal regulatory document required for public offerings or capital raises in Japan, which falls under the 'Regulatory Filings' category as it is a specific legal filing for securities registration.
2025-09-05 Japanese
臨時報告書
Major Shareholding Notification Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is submitted to the Kanto Local Finance Bureau Director. The filing reason explicitly states that it is submitted due to a change in a major shareholder, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 4 of the Cabinet Office Ordinance on Disclosure of Corporate Information. The content details the change in ownership percentage of a major shareholder ('イノベーション京都２０１６投資事業有限責任組合') crossing a threshold (from 10.14% to 9.99%). This specific type of filing in Japan, reporting changes in major shareholdings, corresponds to the Major Shareholding Notification category (MRQ). Although it is a regulatory filing, MRQ is more specific than the general RNS.
2025-05-16 Japanese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.